Vinblastine sulfate

別名: NSC-49842, Vincaleukoblastine, 29060-LE 中文名稱：硫酸長春堿

目錄號(hào)：S4505 Purity: 99.91%

Vinblastine sulfate抑制微管形成和nAChR活性，在無細(xì)胞實(shí)驗(yàn)的測(cè)定中，IC50為8.9 μM。Vinblastine sulfate 可誘導(dǎo)自噬和凋亡。

Vinblastine sulfate Chemical Structure

CAS: 143-67-9

規(guī)格	價(jià)格	庫存
10mM (1mL in DMSO)	794.43	現(xiàn)貨
5mg	573.88	現(xiàn)貨
25mg	2023.45	現(xiàn)貨
100mg	5545.08	現(xiàn)貨
1g	20230.26	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.91%

99.91

Vinblastine sulfate相關(guān)產(chǎn)品

相關(guān)產(chǎn)品	Puromycin Dihydrochloride Staurosporine (STS) Oligomycin A (MCH 32) Nigericin sodium salt Geldanamycin (NSC 122750) Honokiol Streptozotocin (STZ) Sodium Monensin (NSC 343257) Hygromycin B Cephalomannine Pirarubicin 10-Deacetylbaccatin-III Roxithromycin Fumagillin	點(diǎn)擊展開
相關(guān)化合物庫	激酶抑制劑庫血管生成相關(guān)化合物庫 TGF-beta/Smad信號(hào)通路庫細(xì)胞骨架信號(hào)通路化合物庫抗心血管疾病化合物庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述
rat REF52 cells	Function assay	0.1 μM	30 mins	Induction of microtubule depolymerization in rat REF52 cells at 0.1 uM after 30 mins by fluorescence assay
K562 cell	Proliferation assay		48 h	Antiproliferative activity against human K562 cells after 48 hrs, IC50=0.001 μM
ACHN cells	Cytotoxicity assay		48 h	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay, IC50=22.7 μM
A375 cells	Cytotoxicity assay		48 h	Cytotoxicity against human A375 cells after 48 hrs by SRB assay, IC50=7.2 μM
C32 cells	Cytotoxicity assay		48 h	Cytotoxicity against human C32 cells after 48 hrs by SRB assay, IC50=3 μM
LNCAP cells	Cytotoxicity assay		48 h	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay, IC50=29.3 μM
Huh-7D12 cells	Cytotoxicity assay		48 h	Cytotoxicity against human Huh-7D12 cells after 48 hrs by SRB assay, IC50=45.6 μM
COR-L23 cells	Cytotoxicity assay		48 h	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay, IC50=45.5 μM
142BR cells	Cytotoxicity assay		48 h	Cytotoxicity against human 142BR cells after 48 hrs by SRB assay, IC50=37.6 μM
HT-29 cells	Cytotoxicity assay		48 h	Cytotoxicity against human HT-29 cells after 48 hrs by MTS assay, IC50=0.55 μM
A549 cells	Proliferation assay		48 h	Antiproliferative activity against human A549 cells after 48 hrs by MTS assay, IC50=2.36 μM
DU145 cells	Proliferation assay		48 h	Antiproliferative activity against human DU145 cells after 48 hrs by MTS assay, IC50=4.25 μM
SK-MEL-5 cells	Proliferation assay		48 h	Antiproliferative activity against human SK-MEL-5 cells after 48 hrs by MTS assay, IC50=1.74 μM
HepG2 cells	Proliferation assay		48 h	Antiproliferative activity against human HepG2 cells after 48 hrs by MTS assay, IC50=0.16 μM
HT-29 cells	Proliferation assay		48 h	Antiproliferative activity against human HT-29 cells after 48 hrs by MTS assay, IC50=11.18 μM
MCF7 cells	Proliferation assay		48 h	Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay, IC50=24.08 μM
MDA-MB-231 cells	Proliferation assay		48 h	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTS assay, IC50=31.52 μM
HepG2 cells	Cytotoxicity assay		72 h	Cytotoxicity against adriamycin-resistant human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.056 μM
HepG2 cells	Cytotoxicity assay		72 h	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.019 μM
K562 cells	Cytotoxicity assay		72 h	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.016 μM
MDA-MB-231 cells	Cytotoxicity assay		72 h	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.0083 μM
MCF7 cells	Cytotoxicity assay		72 h	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=0.007 μM
UACC903 cells	Cytotoxicity assay		48 h	Cytotoxicity against human UACC903 cells after 48 hrs by MTS assay, IC50=1.65 μM
BxPC3 cells	Proliferation assay		48 h	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTS assay, IC50=1.13 μM
COLO 320 human colorectal carcinoma cell line	Function assay			In vitro concentration required to kill 50% of COLO 320 human colorectal carcinoma cell line, EC50=0.08 μM
LNCaP human prostate cancer cell line	Function assay			In vitro concentration required to kill 50% of LNCaP human prostate cancer cell line, EC50=0.5 μM
K562 cell	Growth inhibition assay			In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth, IC50=0.001 μM
T47D cells	Function assay			In vitro concentration required to kill 50% of T47D human breast ductal carcinoma cell line, EC50=0.08 μM
SCL6 cells	Cytotoxicity assay			Cytotoxicity against human SCL6 cells by MTT assay, ED50=6.1 Μm
SCL9	Cytotoxicity assay			Cytotoxicity against human SCL9 cells by MTT assay, ED=5.3 μM
KATO III cells	Cytotoxicity assay			Cytotoxicity against human KATO III cells by MTT assay, ED50=6.1 μM
NUGC4 cells	Cytotoxicity assay			Cytotoxicity against human NUGC4 cells by MTT assay, ED50=5.3 μM
K562 cells	Function assay			Inhibition of tubulin polymerization in human K562 cells, IC50=0.13 μM
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

Vinblastine sulfate抑制微管形成和nAChR活性，在無細(xì)胞實(shí)驗(yàn)的測(cè)定中，IC50為8.9 μM。Vinblastine sulfate 可誘導(dǎo)自噬和凋亡。

靶點(diǎn)

nAChR
(Adrenal Chromaffin Cells)

8.9 μM

體外研究(In Vitro)
體外研究活性	Vinblastine的平均終末半衰期為14.3小時(shí)。Vinblastine加入到新鮮分離的大鼠肝細(xì)胞，可迅速穿透到細(xì)胞當(dāng)中。Vinblastine抑制由腎上腺髓質(zhì)素誘導(dǎo)的血管生成反應(yīng)，還可引起M期阻滯。在特定濃度下，vinblastine能顯著增加微核單核細(xì)胞的數(shù)量。
細(xì)胞實(shí)驗(yàn)	細(xì)胞系	中國倉鼠卵巢細(xì)胞(CHO)
	濃度	1% (v/v) (dissolved in DMSO)
	孵育時(shí)間	3 h
	方法	6孔細(xì)胞培養(yǎng)板，每孔細(xì)胞密度為5×10⁴ cells/mL，懸浮于3 mL培養(yǎng)基中。向其中加入vinblastine孵育3小時(shí)，生長21小時(shí)后進(jìn)行后續(xù)檢測(cè)。
實(shí)驗(yàn)圖片	檢測(cè)方法	檢測(cè)指標(biāo)	實(shí)驗(yàn)圖片	PMID
	Western blot	GRP78 p-eIF2 p-JNK / c-Caspase-7 / c-PARP ERK / p-ERK / Mcl-1 / Bad / Bid / Noxa		19674193
	Immunofluorescence	α-tubulin / Acetyl tubulin		30120268
	Growth inhibition assay	Cell viability		27114800

體內(nèi)研究(In Vivo)
體內(nèi)研究活性	Vinblastine作為抗癌劑被廣泛運(yùn)用，但具有一些意外的副作用。Vinblastine和RAP在低濃度下的結(jié)合使用，可在體內(nèi)得到比較滿意的抗血管形成作用。在臨床使用劑量下，vinblastine抑制CEM細(xì)胞中的微管蛋白的棕櫚?；?button data-target="s_ref" class="anchor-text">[5]。

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06381570	Recruiting	Low-grade Glioma	Daniel Morgenstern\|The Hospital for Sick Children	March 21 2024	Early Phase 1

參考文獻(xiàn)
[1]https://pubmed.ncbi.nlm.nih.gov/8516349/ [2]https://pubmed.ncbi.nlm.nih.gov/19666138/ [3]https://pubmed.ncbi.nlm.nih.gov/2088769/ [4]https://pubmed.ncbi.nlm.nih.gov/14508526/ [5]https://pubmed.ncbi.nlm.nih.gov/17202812/ + 展開

參考文獻(xiàn)

[1]https://pubmed.ncbi.nlm.nih.gov/8516349/
[2]https://pubmed.ncbi.nlm.nih.gov/19666138/
[3]https://pubmed.ncbi.nlm.nih.gov/2088769/

[4]https://pubmed.ncbi.nlm.nih.gov/14508526/
[5]https://pubmed.ncbi.nlm.nih.gov/17202812/

+ 展開

化學(xué)信息&溶解度

分子量	909.05	分子式	C₄₆H₅₈N₄O₉.H₂SO₄
CAS號(hào)	143-67-9	SDF	Download Vinblastine sulfate SDF
Smiles	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1年-80°C溶于溶劑
儲(chǔ)存條件(自收到貨起)	3年-20°C粉狀	儲(chǔ)備液保存和期限建議分裝儲(chǔ)備液，避免反復(fù)凍融！	1個(gè)月-20°C溶于溶劑

體外溶解度
批次：

DMSO : 100 mg/mL ( (110.0 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : 50 mg/mL (55.0 mM)

Ethanol : Insoluble

DMSO : 100 mg/mL ( (110.0 mM) ；DMSO吸濕會(huì)降低化合物溶解度，請(qǐng)使用新開封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩爾濃度計(jì)算器

體內(nèi)溶解配方批次：現(xiàn)配現(xiàn)用，請(qǐng)按從左到右的順序依次添加，澄清后再加入下一溶劑				動(dòng)物體內(nèi)配方計(jì)算器
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
均勻懸濁液	CMC-NA	≥5mg/ml	以 1 mL 工作液為例，取 5 mg該產(chǎn)品加到 1 ml CMC-NA 溶液中，混合均勻，即可得工作液濃度為 5 mg/ml的均勻懸濁液。
澄清溶液	5%DMSO 1 Corn oil 該配方已經(jīng)過Selleck實(shí)驗(yàn)室實(shí)測(cè)。如果上述溶解方案不能滿足您的需求，可聯(lián)系Selleck銷售提供定制化測(cè)試。	1.670mg/ml (1.84mM)	以 1 mL 工作液為例，取50μL33.3mg/ml的澄清DMSO儲(chǔ)備液加到950μL玉米油中，混合均勻。工作液請(qǐng)現(xiàn)配現(xiàn)用！

實(shí)驗(yàn)計(jì)算

摩爾濃度計(jì)算器

質(zhì)量	濃度	體積	分子量
=	×	×

稀釋計(jì)算器分子量計(jì)算器

動(dòng)物體內(nèi)配方計(jì)算器（澄清溶液）

第一步：請(qǐng)輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動(dòng)物的藥量）

給藥劑量 mg/kg 動(dòng)物平均體重 g 每只動(dòng)物給藥體積 μL 動(dòng)物數(shù)量只

第二步：請(qǐng)輸入動(dòng)物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請(qǐng)聯(lián)系Selleck為您提供正確的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

計(jì)算結(jié)果：

工作液濃度： mg/ml；

DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請(qǐng)先聯(lián)系Selleck）；

體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH₂O，混勻澄清。

體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。

注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。

技術(shù)支持

在訂購、運(yùn)輸、儲(chǔ)存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會(huì)在24小時(shí)內(nèi)盡快聯(lián)系您。

操作手冊(cè)

如果有其他問題，請(qǐng)給我們留言。

* 必填項(xiàng)

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线